I
ncreased diastolic left ventricular (LV) stiffness is recognized as the earliest manifestation of LV dysfunction induced by diabetes mellitus (DM) [1] [2] [3] [4] [5] and frequently becomes the main functional deficit of the diabetic heart, because many diabetic patients present with heart failure (HF) and normal LV ejection fraction (LVEF). 6, 7 This excessive diastolic LV stiffness also modifies ischemic LV dysfunction, as is evident from the reduced LV remodeling and increased incidence of HF after acute myocardial infarction. 8, 9 Clinical Perspective p 51
In the absence of coronary artery disease, excessive diastolic LV stiffness of the diabetic heart has been related to myocardial fibrosis 10 and to circulating advanced glycation end products (AGEs), 11 although associations of histological and biochemical data with in vivo LV function are largely lacking. Furthermore, the contribution of an elevated cardiomyocyte resting tension (F passive ) to this increased diastolic LV stiffness has not been assessed. In patients with HF and normal LVEF (HFNEF), F passive of cardiomyocytes isolated from LV endomyocardial biopsy samples was recently demonstrated to be elevated and to be an important determinant of LV stiffness. 12 In patients with HF and reduced LVEF (HFREF), F passive was lower and failed to correlate with LV stiffness. 13 The high F passive in HFNEF was paralleled by cardiomyocyte hypertrophy and concentric LV remodeling. 12, 13 Because myocardial hypertrophy is associated with insulin resistance, 14 and because HFNEF is common in patients with type 2 DM, 7 high F passive could be an important contributor to the excessive diastolic LV stiffness of the diabetic heart.
Using LV endomyocardial biopsy samples, we therefore compared myocardial fibrosis, AGE deposition, and F passive of isolated cardiomyocytes between diabetic (DM ϩ ) and nondiabetic (DM Ϫ 
Methods Patients
The study population consisted of 90 patients hospitalized for worsening HF between October 2003 and December 2006. Patients were referred for cardiac catheterization and LV endomyocardial biopsy procurement because of suspicion of infiltrative or inflammatory myocardial disease. Fifty-eight patients had new-onset HF, and 32 had acute decompensation superimposed on chronic HF. Modes of presentation were similar in HFNEF versus HFREF patients and in DM ϩ versus DM Ϫ patients. Patients were studied after medical compensation. No patient had undergone cardiac transplantation. Coronary angiography showed epicardial coronary artery stenoses in 20 patients; these patients were excluded from the present study. Histological analysis of the biopsy samples revealed active inflammatory infiltration or myocardial deposits in 6 patients. The histologically positive biopsy sample rate of 8.6% of the study population is comparable to the rate found in previous studies, which reported active lymphocytic infiltration in 8.3% of patients with dilated cardiomyopathy 15 and amyloid deposits in 6.3% of patients with LV restrictive physiology 16 of hemodynamic severity comparable to that of the present study population. Patients with a positive biopsy sample were also excluded from the present study. The final study cohort, therefore, consisted of 64 patients. For 44 of these 64 patients, data on myocardial collagen volume fraction (CVF) and cardiomyocyte F passive were included in previous studies. 12, 13 In accordance with a recent consensus document on the diagnosis of HFNEF, 17 patients had HFNEF (nϭ28) if LVEF was Ͼ50%, LV end-diastolic volume index was Ͻ97 mL/m 2 , and LV end-diastolic pressure was Ͼ16 mm Hg. 17 Patients had HFREF (nϭ36) if LVEF was Ͻ45%. A patient had DM if a history of DM was evident from use of glucose-lowering medications and/or insulin or if fasting plasma glucose was Ն7.0 mmol/L. 18 No patient was using thiazolidinediones. Three HFREF patients had type 1 DM, and 7 HFREF and all 16 HFNEF patients had type 2 DM. In DM ϩ HFREF and DM ϩ HFNEF patients who were not undergoing insulin therapy, fasting insulin plasma levels were elevated (20.1Ϯ4.3 and 22.4Ϯ3.0 U/mL, respectively). The local ethics committee approved the study protocol. Written informed consent was obtained from all patients.
Quantitative Histomorphometry

Light and Electron Microscopy
Light microscopic quantification of cardiomyocyte diameter and CVF has been described and validated previously. 12, 13 Biopsy samples used for CVF averaged 2.8Ϯ0.2 samples per patient. The same automated image analyzer was also used for electron microscopic quantification 13 of the sarcomeric Z-line thickness of cardiomyocytes. For each patient, 30 Z-line-thickness measurements were averaged.
Immunohistochemistry
Deposition of AGEs was inferred from measurement of the AGE N -(carboxymethyl)lysine (CML). Development of the anti-CML monoclonal antibody and immunohistochemical staining techniques for CML and E-selectin used in the present study have been described previously. 19, 20 AGE and E-selectin positivity was scored for intensity. The sum of all positivities times their score was subsequently divided by the area of the slide to yield an immunohistochemical score per square millimeter (score/mm 2 ). 
Immunofluorescence Light Microscopy
Force Measurements in Isolated Cardiomyocytes
Force measurements were performed in single, mechanically isolated cardiomyocytes as described previously. 12 
Data Analysis
LV end-diastolic volume, LV end-diastolic volume index, LV stroke volume, and LVEF were derived from biplane LV angiograms. Effective arterial elastance was equal to LV end-systolic pressure divided by angiographic LV stroke volume. Total arterial compliance equaled angiographic LV stroke volume divided by aortic pulse pressure. LV diastolic internal diameter (LVIDd), diastolic septal and posterior wall thicknesses (SWTd and PWTd, respectively), relative wall thickness (RWT), LV mass (LVM), and LV mass index were derived from 2-dimensional echocardiograms. LV mass and relative wall thickness were calculated in accordance with the recent recommendations for cardiac chamber quantification, 21 as follows:
LVMϭ0.8ϫ͕1.04͓͑LVIDdϩPWTdϩSWTd͒
3 ϪLVIDd 3 ͔͖ϩ0.6 g and RWTϭ2ϫPWTd/LVIDd
To calculate LV peak systolic wall stress (LVPSs) and LV myocardial stiffness modulus (SM), hemodynamic, angiographic, and 2D echocardiographic data were combined. Circumferential LVPSs was computed with a thick-wall ellipsoid model of the LV as follows 22 :
where LVPSP is LV peak systolic pressure, PWTs is the corresponding systolic echocardiographic posterior wall thickness, and D and L are the corresponding angiographic LV systolic diameter and length, respectively.
To assess diastolic LV material properties, a radial LV SM was derived. 23 SM was defined as the increment of radial stress (⌬) divided by the increment of radial strain (⌬⑀) (sMϭ⌬/⌬⑀). ⌬ is equal but opposite in sign to the increment of LV pressure (LVP) at the endocardium (Ϫ⌬LVP), and ⌬⑀ equals the increment in 2-dimensional echocardiographic posterior wall thickness (PWT) relative to the instantaneous PWT (⌬PWT/PWT). Early diastolic LV relaxation pressure was extrapolated from the exponential curve fit to isovolumic LV pressure decay, which was used to calculate , the time constant of isovolumic LV pressure decay. Early diastolic LV relaxation pressure was subtracted from measured LVP to yield residual LV diastolic pressure (LVP res ). Substitution of LVP by LVP res allowed the SM to also be calculated in early diastole, when LVP is still declining. 23 Because ⌬PWT/PWTϭ⌬lnPWT, SM equals the slope of a plot of LVP res against corresponding ⌬lnPWT data points.
Values are given as meanϮSEM. Data of the DM The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
DM and LV Function
As evident from the higher LV end-diastolic pressure at similar LV end-diastolic volume index, LV end-diastolic distensibility was reduced in DM 
Myocardial AGE Deposition and Fibrosis
AGE deposition was inferred from CML immunostaining and occurred mainly in the wall of small intramyocardial vessels (Figure 2A) . In 2-factor ANOVA, CML deposition depended on the presence of DM (PϽ0.001) but not on HFNEF/HFREF status. CML deposition was especially evident when DM Figure 2B ). CML deposition correlated with the myocardial SM in HFREF (rϭ0.48, Pϭ0.014). The DM-induced rise in myocardial CML deposition in HFREF was paralleled by a rise in E-selectin expression from 3.6Ϯ0.9 to 9.2Ϯ1.9 score/mm 2 (Pϭ0.022). E-selectin is a marker of inflammatory endothelial activation ( Figure 2C) .
In 2-factor ANOVA, myocardial CVF depended on DM (Pϭ0.006) and on HFNEF/HFREF status (PϽ0.001). Moreover, the effect of DM on CVF depended on HFNEF/HFREF status (Pϭ0.007). CVF was higher when DM Figure 2D ). In HFREF patients, CVF correlated with SM (rϭ0.37, Pϭ0.039) and with plasma glycohemoglobin (rϭ0.61, Pϭ0.0014).
Myocyte F passive , Myocyte Hypertrophy, and LV Remodeling
In all cardiomyocytes, F passive was measured at the same sarcomere length of 2.2 m ( Figure 3A) . In 2-factor ANOVA, F passive depended on DM (Pϭ0.009) and on HFNEF-HFREF status (PϽ0.001). Similar to myocardial CVF, the effect of DM on F passive was dependent on HFNEF-HFREF status (Pϭ0.021). F passive of DM Figure 3D ) and on electron microscopy images (ϩ15.2%, PϽ0.001; Figure 3E ). In HFNEF patients, F passive correlated with SM (rϭ0.55, Pϭ0.022) and with the duration of DM (rϭ0. 35, Pϭ0.04) .
In control conditions, F passive rose progressively from HFREF to DM 
Discussion
The prevalence of DM in heart failure is increasing, 24, 25 and mortality and hospitalization rates in diabetic patients with heart failure remain particularly high. 26 -28 Although coronary artery disease is the most important contributor to the myocardial dysfunction observed in DM, DM-related disturbances such as hyperglycemia, insulin resistance, and hyperlipidemia can also act directly on the myocardium 29 and induce myocardial dysfunction because of a shift in myocardial energy production from glucose utilization to fatty acid oxidation. 30 -32 In the first clinical description of DM-induced myocardial dysfunction, LV dilatation and systolic LV dysfunction were prominent features, 33 and DM-induced myocardial dysfunction was therefore classified as a dilated cardiomyopathy. Subsequently, diastolic LV dysfunction was recognized as an earlier manifestation of DM-induced myocardial dysfunction. [1] [2] [3] [4] [5] The present study confirmed diastolic LV stiffness to be greater in failing hearts of diabetic patients in the absence of significant coronary artery disease. Mechanisms responsible for this DM-induced diastolic myocardial stiffening were identified in endomyocardial biopsy samples of these patients. The main finding of the present study is that DM elevated diastolic LV stiffness by different mechanisms in HFREF and HFNEF patients. In HFREF, DM elevated diastolic LV stiffness through myocardial AGE deposition and fibrosis, whereas in HFNEF, DM increased diastolic LV stiffness mainly through higher F passive of hypertrophied cardiomyocytes. 
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property of collagen increases diastolic LV stiffness. AGE deposition can also indirectly augment diastolic LV stiffness through enhanced collagen formation and reduced nitric oxide bioavailability. Enhanced collagen formation in the presence of AGEs was observed in the present study. AGEs quench endothelially produced nitric oxide, and low myocardial nitric oxide bioavailability was previously demonstrated to increase diastolic LV stiffness in HFREF patients. 36 Previous myocarditis, not DM, is the most likely cause of the dilated cardiomyopathy in the majority of the DM ϩ HFREF patients, because fasting glucose, glycohemoglobin, and DM duration were all similar in the DM ϩ HFREF and DM ϩ HFNEF groups. Even in the absence of cellular infiltration, patients with postmyocarditis HFREF frequently have persistent myocardial microvascular inflammation. 37 Inflammation facilitates AGE deposition, 20, 38 and persistent microvascular inflammation could therefore explain the preferential CML deposition in small intramyocardial vessels of DM ϩ HFREF patients. In rodent DM animal models, AGE deposition also occurs in the myocardial interstitium. 39 Failure to observe interstitial CML deposition in the present study probably relates to better glycemic control in patients treated with glucose-lowering medication or insulin than in untreated rodent animal models. The clinical importance of endothelial AGE deposition was recently confirmed in hypertensive patients in whom a cross-link breaker improved endothelial function. 40 In the present study, we observed a higher CVF in DM ϩ HFREF than in DM Ϫ HFREF patients. Activation of fibroblasts in DM ϩ HFREF patients may have resulted from the aforementioned AGE deposition, protein kinase C activation, or high intracellular glucose concentrations. 35, 41 Cardiomyocyte Resting Tension DM ϩ HFNEF patients had a higher SM than DM Ϫ HFNEF patients. The higher SM related more to cardiomyocyte F passive and less to AGE deposition. Correction of high cardiomyocyte F passive by protein kinase A suggests a phosphorylation deficit of myofilamentary or cytoskeletal proteins, 12, 13 because the cardiomyocytes had been pretreated with Triton X-100 to remove all membranes. High F passive of DM ϩ HFNEF cardiomyocytes was accompanied by Z-line widening. Z-line widening has been observed in transgenic mice after nebulin or muscle LIM protein knockout. 42, 43 The present study is the first to report Z-line widening in humans, and because of the simultaneous elevation of F passive , it suggests that Z-line widening results from altered elastic properties of cytoskeletal proteins, which pull at and open up adjacent Z lines. In a previous study comparing HFREF with HFNEF, 13 a significant correlation was observed between cardiomyocyte hypertrophy and F passive . In the present study, F passive rose progressively from HFREF to DM Ϫ HFNEF and to DM ϩ HFNEF , and this rise was paralleled by an increase in cardiomyocyte diameter and a shift from eccentric to concentric LV remodeling. Because LV peak systolic pressure and peak systolic wall stress were similar in DM ϩ HFNEF and DM Ϫ HFNEF , excess cardiomyocyte hypertrophy in DM ϩ HFNEF was unrelated to pressure overload and was probably induced by insulin resistance. 14 All of the DM ϩ HFNEF patients had type 2 DM and elevated fasting insulin plasma levels. Furthermore, hyperinsulinemia is known to stimulate prohypertrophic signaling in insulinresponsive tissues such as the myocardium. 29 
Study Limitations
The clinical characteristics of the HFNEF patients in the present study differed from clinical characteristics observed in epidemiological studies. In the present study, HFNEF patients were younger (mean age 64 years) and less often female (46%) than in epidemiological studies, 44 in which patients are typically older (mean age 76 years) and more often female (55%). Patient recruitment from tertiary referral because of suspicion of inflammatory or infiltrative myocardial disease explains this discrepancy.
In the present study, diastolic LV material properties were analyzed by a radial LV SM. Use of a radial LV SM avoids geometric assumptions of LV shape. Furthermore, substitution of measured LVP by LVP res enables early diastole to be included in the LV stiffness analysis, because it corrects for the upward displacement of the early diastolic LV pressure-volume relation. 45 In a previous study 46 of HFREF patients, close agreement was observed between the radial LV SM and the LV chamber stiffness constant derived from a curve fit to multiple LV end-diastolic pressure-volume points during balloon caval occlusion.
Higher LV end-diastolic pressure at similar or smaller LV end-diastolic volume can result from altered myocardial material properties and from external constraints on the LV by the right ventricle or the pericardium. 47 Right ventricular constraints because of the shared interventricular septum are prominent in patients with hypertrophic cardiomyopathy but not in patients with HFNEF, who usually have hypertensive heart disease. 47 Right atrial pressure was determined as a measure of intrapericardial pressure or pericardial constraint and was comparable in all patient groups.
Because of microvascular CML deposition, a relative reduction of the number of microvessels in hypertrophied myocardium could have lowered the CML score in the DM ϩ HFNEF patients. A similar CML score in DM Ϫ HFNEF and DM Ϫ HFREF patients, however, argues against such an artifact. Isolation of cardiomyocytes and assessment of myocardial tissue properties were performed on a limited number of samples procured by an endomyocardial biopsy technique and potentially overlook tissue heterogeneity. The extent of tissue heterogeneity was assessed in the present and previous 12,48 studies. Sampling-related variability was Ͻ5% for cardiomyocyte force measurements and Ͻ15% for histomorphometric data.
Development of HFNEF results from diastolic LV dysfunction, 44 deficient chronotropic or vasomotor responses, 49, 50 and arterial stiffening. 45 In DM, not only diastolic LV dysfunction but also arterial stiffness becomes a more important contributor to HFNEF.
Conclusions
In the absence of coronary artery disease, the failing diabetic heart has an elevated diastolic LV stiffness. Mechanisms responsible for this increase in diastolic LV stiffness differ between HFREF and HFNEF patients. Deposition of AGEs and deposition of collagen are important determinants of the increased LV stiffness in diabetic patients with HFREF, whereas high cardiomyocyte F passive is the main determinant of the increased LV stiffness in diabetic patients with HFNEF.
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